Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPLSG-ALL-T19 multicenter phase II study in children and adults with newly diagnosed T-cell acute lymphoblastic leukemia
jRCTs041210054Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of asparaginase escherichia coli in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Three-year event-free survival (overall cohort). Started Aug 2021; status: active, not recruiting.
02
Drugs
asparaginase escherichia coli
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041210054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210054.